ViroCell Biologics is an innovation-focused CDMO that manufactures viral vectors and gene-modified cells that enable novel cell and gene therapies to enter clinical trials. Founded in 2020, the company is headquartered in London. With their experienced staff and state-of-the-art facilities, they develop tailored design and manufacturing strategies for each client. ViroCell is focused exclusively on the design, optimization, and GMP manufacturing of viral vectors for clinical trials.
